Valuation : Nipro Corporation

Market Cap 25TCr 159.51Cr 137.61Cr 129.63Cr 118.11Cr 220.76Cr 15TCr 222.41Cr 1.53TCr 595.59Cr 7.7TCr 598.96Cr 585.86Cr P/E 2027 *
15.7x
P/E 2028 * 11.9x
Enterprise Value 75TCr 475.23Cr 409.98Cr 386.21Cr 351.88Cr 657.73Cr 45TCr 662.66Cr 4.57TCr 1.77TCr 23TCr 1.78TCr 1.75TCr EV / Sales 2027 *
1.08x
EV / Sales 2028 * 1.02x
Free-Float
84.43%
Yield 2027 *
2.36%
Yield 2028 * 2.96%
31/07 Nipro Corporation Receives Fda 510(K) Clearance for Elisio-Hx Dialyzer and Introduces Hds to the United States CI
29/07 Vat Holding AG agreed to acquire 100% stake in Atonarp Inc. from Nipro Corporation for CHF 110 million. CI
14/07 Jefferies Adjusts Nipro's Price Target to 1,700 Yen From 1,500 Yen, Keeps at Hold MT
12/05 Nipro Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and Fiscal Year Ending March 31, 2027 CI
12/05 Nipro Corporation Announces Year-End Dividend for Fiscal Year Ended March 31, 2026, Payable on June 10, 2026; Provides Second Quarter-End and Year-End Dividend Guidance for Fiscal Year Ending March 31, 2027 CI
01/05 Jefferies Adjusts Nipro's Price Target to 1,500 Yen From 1,300 Yen, Keeps at Hold MT
11/03 Nipro Fixes Record Date for Fiscal 2026 Year-End Dividend MT
09/02 Nipro Corporation Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
24/12 Nipro Corporation Announces Establishment of Wholly Owned Subsidiary in Singapore CI
10/11 Nipro Corporation Announces Dividend for the Second Quarter End of Fiscal Year Ending March 31, 2026, Payable on December 10, 2025 CI
10/25/10 Samsung Bioepis Partners With Nipro to Commercialize Biosimilars in Japan MT
09/25/09 Samsung Bioepis Co., Ltd. Enters into A Strategic Partnership with NIPRO Corporation for Commercialization of Multiple Biosimilars in Japan CI
13/25/13 Jefferies Adjusts Nipro's Price Target to 1,300 Yen from 1,400 Yen, Keeps at Hold MT
1 day-1.31%
1 week-1.93%
Current month-2.24%
1 month-6.59%
3 months-13.35%
6 months-5.21%
Current year+1.73%
1 week 1,501.5
Extreme 1501.5
1,553
1 month 1,501.5
Extreme 1501.5
1,684.5
Current year 1,401
Extreme 1401
1,760.5
1 year 1,401
Extreme 1401
1,760.5
3 years 1,041
Extreme 1041
1,760.5
5 years 987
Extreme 987
1,760.5
10 years 908
Extreme 908
1,760.5
Manager TitleAgeSince
Director of Finance/CFO 57 01/06/2025
President 58 01/06/2025
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 81 26/06/2025
Director/Board Member 53 01/06/2009
Director/Board Member 58 01/06/2009
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%-1.93%-2.18%+22.85% 159.51Cr
+1.41%-3.18%-15.97%+7.41% 19TCr
+0.15%+0.17%-1.23%+12.24% 12TCr
+1.63%+2.61%+14.08%+92.25% 6.42TCr
-0.02%-0.20%+25.04%+48.51% 5.15TCr
+0.21%-1.41%-0.33%-32.66% 5.11TCr
-0.50%+0.82%+20.71%-11.98% 3.38TCr
+3.39%+4.97% - - 3.18TCr
+1.18%-2.08%+40.57%-15.96% 2.41TCr
-0.43%-3.98%-6.61%+13.17% 2.3TCr
Average +0.52%-1.14%+8.23%+15.09% 5.9TCr
Weighted average by Cap. +0.77%-1.96%+0.90%+16.40%

Financials

2027 *2028 *
Net sales 70TCr 441.88Cr 381.21Cr 359.11Cr 327.19Cr 611.58Cr 42TCr 616.16Cr 4.25TCr 1.65TCr 21TCr 1.66TCr 1.62TCr 73TCr 459.37Cr 396.3Cr 373.32Cr 340.14Cr 635.78Cr 43TCr 640.55Cr 4.42TCr 1.72TCr 22TCr 1.72TCr 1.69TCr
Net income 1.54TCr 9.7Cr 8.37Cr 7.89Cr 7.18Cr 13Cr 916.55Cr 14Cr 93Cr 36Cr 468.6Cr 36Cr 36Cr 2TCr 13Cr 11Cr 10Cr 9.31Cr 17Cr 1.19TCr 18Cr 121.01Cr 47Cr 607.42Cr 47Cr 46Cr
Net Debt 50TCr 315.72Cr 272.38Cr 256.58Cr 233.78Cr 436.97Cr 30TCr 440.25Cr 3.04TCr 1.18TCr 15TCr 1.19TCr 1.16TCr 49TCr 308.35Cr 266.01Cr 250.59Cr 228.32Cr 426.76Cr 29TCr 429.96Cr 2.97TCr 1.15TCr 15TCr 1.16TCr 1.13TCr
Logo Nipro Corporation
Nipro Corp is a Japan-based company mainly engaged in the medical, pharmaceutical, and pharma packaging businesses. It has three segments. The Medical segment consists of the domestic business division and the international business division. The domestic business division sells medical devices related to injections and infusions, artificial organs, high-performance medicines, and dialysis. The international business division, centered on the head office, has medical device manufacturing and sales bases overseas for regional expansion, selling medical devices related to injections and infusions, artificial organs, and diabetes. The Pharmaceutical segment sells pharmaceuticals related to kit preparation containers on a contract basis from pharmaceutical companies. The Pharma Packaging segment sells medical glass products such as glass tubes and ampoules, thermos flasks, and kit preparation containers in Japan.
Employees
38,593
Date Price Change Volume
03/26/03 JP¥1,502.50 -1.31% 3,99,700
02/26/02 JP¥1,522.50 -1.96% 7,20,600
01/26/01 JP¥1,553.00 +1.04% 6,20,200
31/26/31 JP¥1,537.00 +0.59% 7,13,600
28/26/28 JP¥1,528.00 -0.26% 7,97,600
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1,522.50JPY
Average target price
1,996.00JPY
Spread / Average Target
+31.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 8086 Stock